A responsive outcome for Parkinson's disease neuroprotection futility studies

Futility studies are designed to test new treatments over a short period in a small number of subjects to determine if those treatments are worthy of larger and longer term studies, or if they should be abandoned. An appropriate outcome measure for a neuroprotection futility study in Parkinson's disease (sensitive to tracking disease progression in the short‐term) has not been determined. Data sets from three clinical trials were used to compare Parkinson's disease outcome measures. Total Unified Parkinson's Disease Rating Scale (UPDRS; Mentation + Activities of Daily Living + Motor) change and Motor plus Activities of Daily Living UPDRS change, measured in untreated patients, required the smallest sample sizes of all the outcome measures explored. Other outcomes (UPDRS Motor, UPDRS Activities of Daily Living, and time to need levodopa) required somewhat larger sample sizes. Futility designs in Parkinson's disease are feasible in terms of short duration and small sample size requirements, and this design is being applied in two ongoing Parkinson's disease studies to select agents for future larger and longer term neuroprotection studies. Ann Neurol 2005;57:197–203

[1]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[2]  A. Beck,et al.  An inventory for measuring depression. , 1961, Archives of general psychiatry.

[3]  B. Djahanguiri,et al.  The prevention of acute gastric ulcer in the rat by alpha-methyldopa. , 1967, Medicina et pharmacologia experimentalis. International journal of experimental medicine.

[4]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[5]  Z. Schwab,et al.  Projection technique for evaluating surgery in Parkinson’s disease , 1969 .

[6]  J. Turner.  Third Symposium on Parkinson's Disease , 1970 .

[7]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[8]  J. Herson,et al.  Predictive probability early termination plans for phase II clinical trials. , 1979, Biometrics.

[9]  D. Schoenfeld,et al.  Statistical considerations for pilot studies. , 1980, International journal of radiation oncology, biology, physics.

[10]  M. Mccracken.  Clinical trials in oncology. , 1982, Clinical oncology.

[11]  C. Marsden,et al.  Recent Developments in Parkinson's Disease , 1986 .

[12]  S. Fahn.  Unified Parkinson's Disease Rating Scale , 1987 .

[13]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[14]  DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. , 1989, Archives of neurology.

[15]  W. Landau.  Clinical Neuromythology IX — Pyramid sale in the bucket shop , 1990, Neurology.

[16]  C. Ward,et al.  Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[17]  David Oakes,et al.  The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol , 1997 .

[18]  P. Lewitt,et al.  The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group. , 1997, Movement disorders : official journal of the Movement Disorder Society.

[19]  K. Sobue,et al.  Molecular Mechanism of Phenotypic Modulation of Smooth Muscle Cells , 1998, Hormone Research in Paediatrics.

[20]  R. Capildeo.  Implications of the 5-year CR FIRST trial , 1998, Neurology.

[21]  A. Takahashi.  Rating scale for depression , 1998 .

[22]  A. Korczyn,et al.  A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease , 1999, Neurology.

[23]  A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson's Disease: Design and Methods of the CALM-PD Study , 2000 .

[24]  A. Bonnet.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[25]  A. Destée,et al.  Five-Year Follow-Up of Early Lisuride and Levodopa Combination Therapy versus Levodopa Monotherapy in de novo Parkinson’s Disease , 2000, European Neurology.

[26]  Joel S Perlmutter,et al.  Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.

[27]  Alison Abbott,et al.  Neurologists strike gold in drug screen effort , 2002, Nature.

[28]  Barbara Gandek,et al.  Sf-12v2 How to score version 2 of the sf-12 health survey. Quality Metric Incorporated , 2002 .

[29]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[30]  Joseph W Hogan,et al.  Handling drop‐out in longitudinal studies , 2004, Statistics in medicine.

[31]  A. Schapira,et al.  Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.

[32]  S Fahn,et al.  Evaluation of the pull test technique in assessing postural instability in Parkinson’s disease , 2004, Neurology.

[33]  Ims Study Investigators.  Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study , 2004, Stroke.

[34]  Mona L. Martin,et al.  Quality of life and parkinson's disease: Translation and validation of the US Parkinson's Disease Questionnaire (PDQ-39) , 1999, Quality of Life Research.

[35]  E. Bézard,et al.  Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment , 2004, Neurology.

[36]  Barbara Gandek,et al.  How to score version 2 of the SF-12(R) health survey (with a supplement documenting version 1) , 2005 .

[37]  N. Breslow.  Clinical Trials—I , 2006 .

[38]  Ims Ii Trial Investigators,et al.  The Interventional Management of Stroke (IMS) II Study , 2007 .